Evaluation of the Pharmacokinetics and Safety of AMG 986 Tablet and Capsule Formulations in Healthy Adult Subjects: A Phase I, Open-Label, Randomized Study

Abstract

Background and objective AMG 986 is a first-in-class, novel apelin receptor small molecule agonist initially developed for the treatment of heart failure. The current phase I study was conducted to evaluate the pharmacokinetics and safety of a single-dose 200-mg capsule formulation of AMG 986 relative to the tablet formulation in 12 healthy subjects. Methods In a two-period, two-way crossover design, eligible subjects were randomized 1:1 to tablet/capsule or capsule/tablet treatment sequences; each treatment sequence lasted for approximately 6 days and comprised six subjects. Results Following a single oral dose of AMG 986, the geometric mean maximum observed concentration ( C max ) values were 9670 ng/mL and 6920 ng/mL and the geometric mean area under the curve from time zero to 120 h (AUC 0–120h ) values were 68,000 ng*h/mL and 59,900 ng*h/mL for the tablet and capsule, respectively. The geometric least squares means (90% confidence interval [90% CI]) for the ratios of capsule/tablet were 0.88 (90% CI 0.81–0.96) and 0.72 (90% CI 0.57–0.91) for AUC 0–120h and C max , respectively. AMG 986 had an acceptable safety profile; all adverse events were grade 1 or 2 in severity. Conclusion There was a modest 12% decrease in AUC 0–120h and a 28% decrease in C max with the AMG 986 capsule versus the tablet. These differences are not considered to be clinically relevant, suggesting the capsule formulation can be used in subsequent clinical studies of AMG 986. Supplementary Information The online version contains supplementary material available at 10.1007/s40268-022-00388-1.

Pharmacokinetics, Bioequivalence and Safety of Cloperastine in Chinese Healthy Subjects Under Fasting and Postprandial Conditions

“…Therefore, this study evaluated the PK of cloperastine tablets in healthy Chinese subjects to better understand its in vivo characteristics. The BE between the generic preparation produced by Dior Group Chengdu Pharmaceutical Co., Ltd., China and the original preparation was also evaluated to provide a reference for its approval as a generic drug in China [14][15][16].…”

Signaling Modulation via Minimal C-Terminal Modifications of Apelin-13

“…They obtained agonists with good affinity and stability, but without studying the potential for signaling bias . In addition, many efforts have been made in recent years to develop small molecule agonists of the APJ receptor. ,− Nevertheless, the development of peptide analogues allows an easy and rapid approach for structure–activity relationship (SAR) studies and functional selectivity, which is still poorly understood.…”